The U.S. Food and Drug Administration today approved BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) Vimizim (elosulfase alfa), the first FDA-approved treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE